Group 1: Company Strategy and Business Focus - The company is committed to focusing on its core business, emphasizing the "big health" development strategy in pharmaceuticals and healthcare [2] - In pharmaceuticals, the company aims to enhance its integrated development model, covering raw materials, formulations, functional skincare products, and skin health management [2][3] - The healthcare segment includes basic medical care, rehabilitation, and longevity services, creating a comprehensive health ecosystem for customers [2][4] Group 2: Pharmaceutical Business Overview - The pharmaceutical business involves the research, production, and sales of drug formulations and raw materials, with a focus on skin, anti-infection, and anti-tumor products [3] - The company has three raw material production bases, ensuring a stable supply of core products and establishing long-term partnerships with international pharmaceutical companies [3] - The company holds a 13.2% stake in a gene therapy company, making it the third-largest shareholder [3] Group 3: Healthcare Services - The healthcare services include basic medical treatment, rehabilitation, and health management, providing integrated services to improve patient health and longevity [4][5] - The company operates various medical institutions that collaborate on resources, technology, and training to enhance service quality [7] Group 4: Tourism Business - The tourism segment includes operations in scenic area transportation, hotel management, and tourism performances, primarily in five major 5A scenic spots [9] - The company aims to enhance its core competitiveness and improve management levels across its business segments, including tourism [9] Group 5: Financial Performance Projections - For 2025, the company expects a net profit attributable to shareholders between 66 million and 73 million, representing a year-on-year growth of 320.74% to 344.16% [9] - The net profit after excluding non-recurring gains is projected to be between 60 million and 67 million, indicating a growth of 277.59% to 298.31% compared to the previous year [9]

证券代码：002004 证券简称：华邦健康 公告编号：2026010 华邦生命健康股份有限公司 关于非公开发行科技创新可交换公司债券发行完成 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于 2025 年 12 月 24 日在巨 潮资讯网（www.cninfo.com.cn）等指定信息披露媒体上发布了《关于非公开发行 科技创新可交换公司债券的公告》（公告编号：2025058）。拟面向专业机构投 资者非公开发行科技创新可交换公司债券，债券的种类为可交换为山东凯盛新材 料股份有限公司 A 股股票（股票代码：301069.SZ）的公司债券。 1 截至 2026 年 3 月 24 日，本期可交换债券已发行完成，本期可交换债券的相 关信息如下： 1、债券简称：26 华邦 EB 2、发行规模：人民币 9.60 亿元 3、债券期限：3 年 4、换股期限：自本期可交换债券发行结束之日满 6 个月后的第一个交易日 起至本期可交换债券到期日前一交易日止。 特此公告。 华邦生命健康股份有限公司 董 事 会 2026 年 3 ...

证券代码：002004 证券简称：华邦健康 公告编号：2026009 二、本无异议函不表明本所对债券的投资风险或者收益等作出判断或者保证。 你公司应当确保参与债券认购的投资者符合本所投资者适当性管理规定，并向其 充分揭示风险。 1 三、债券的发行应当按照报送本所的相关文件进行，如发行人相关情况或债 券相关文件在本无异议函出具之后发生重大变化，应当及时报告本所。如发生重 大变化未及时告知本所的，本无异议函自动失效。 四、你公司应当自本无异议函出具之日起十二个月内正式向本所提交挂牌转 让申请文件，逾期未提交的，本无异议函自动失效。" 华邦生命健康股份有限公司 关于收到《关于华邦生命健康股份有限公司非公开 发行科技创新可交换公司债券符合深交所挂牌条件 的无异议函》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）分别于 2025 年 12 月 23 日召开第九届董事会第四次会议、2026 年 1 月 12 日召开 2026 年第一次临时股 东会，审议通过了以本公司所持的山东凯盛新材料股份有限公司（股票代码： 3010 ...

Report Summary 1. Industry Investment Rating No industry investment rating information is provided in the report. 2. Core View The report regularly tracks the latest private exchangeable bond (private EB) projects from public channels, providing basic element tracking for private exchangeable bond projects. It emphasizes that the private issuance terms and processes may change, and the final prospectus should be referred to. For the issuance progress, inquiries should be made with the relevant lead underwriters [1]. 3. Weekly New Project Information - **HuaBang Life Science Co., Ltd.**: In 2026, the project of privately issuing science - and - technology innovation exchangeable corporate bonds to professional investors was approved by the exchange. The proposed issuance scale is 1 billion yuan, the underlying stock is Kaisheng New Materials (301069.SZ), the lead underwriters are Huatai United and Southwest Securities, and the exchange update date is March 3, 2026 [1]. - **Liaoning Chengda Co., Ltd.**: In 2026, the project of privately issuing exchangeable corporate bonds to professional investors was accepted by the exchange. The proposed issuance scale is 4 billion yuan, the underlying stock is GF Securities (000776.SZ), the lead underwriter is CITIC Construction Securities, and the exchange update date is March 4, 2026 [1]. 4. Table of Private EB Weekly Tracking (2026 - 3 - 6) The table lists information on multiple private exchangeable bond projects, including bond names, lead underwriters, scales, underlying stocks, project statuses, and update dates. Projects are in different statuses such as "Passed", "Feedback Received", and "Accepted" [3].

证券代码：002004 证券简称：华邦健康 公告编号：2026008 华邦生命健康股份有限公司 关于使用暂时闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：低风险、流动性好、安全性高的短期（不超过一年）理财产 品，包括但不限于商业银行、非银行金融机构发行的低风险型理财产品、结构性 存款产品、固定收益凭证等。 2、投资金额：华邦生命健康股份有限公司（以下简称"公司"）及下属子公 司购买理财产品额度不超过人民币 280,100 万元，在该额度内资金可以滚动使用。 3、特别风险提示：公司及下属子公司使用闲置自有资金进行现金管理所涉 及的产品属于商业银行、非银行金融机构发行的低风险理财产品，但金融市场受 宏观经济的影响较大，不排除该投资受到市场波动的影响。 一、投资情况概述 （一）投资目的 为提高资金使用效率，合理利用闲置资金，在不影响公司正常经营和主营业 务发展的前提下，利用闲置自有资金购买商业银行、非银行金融机构低风险、流 动性好、安全性高的短期（不超过一年）理财产品，增加公司现金资产收益。 （二）投资 ...

证券代码：002004 证券简称：华邦健康 公告编号：2026007 华邦生命健康股份有限公司 第九届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （二）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2026 年度财务预算报告》。 二、备查文件 第九届董事会第五次会议决议。 特此公告。 华邦生命健康股份有限公司 董 事 会 2026 年 3 月 6 日 一、会议召开及议案审议情况 华邦生命健康股份有限公司（以下简称"公司"）第九届董事会第五次会议通 知于 2026 年 3 月 2 日以电子邮件的形式发出，2026 年 3 月 5 日通过通讯表决的 方式召开，公司 6 名董事都参加了本次会议，会议的通知及召开符合《公司法》 及《公司章程》的规定，合法有效。会议由公司董事长张松山先生主持，经与会 各位董事认真讨论研究，审议并通过了如下议案： （一）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于 使用暂时闲置自有资金进行现金管理的议案》。 详见公司同日在《中国证券报》《证券时报》《上海证券报》及巨潮 ...

Group 1: Company Strategy - The company focuses on the "big health" development strategy in pharmaceuticals and medical services, aiming to create a comprehensive health ecosystem covering the entire lifecycle of customers [2] - It aims to enhance core competitiveness by concentrating on its main business and improving management levels across various sectors [3] Group 2: Financial Performance - The company forecasts a net profit attributable to shareholders for 2025 between CNY 660 million and CNY 730 million, representing a year-on-year growth of 320.74% to 344.16% [2] - The net profit after deducting non-recurring gains and losses is expected to be between CNY 600 million and CNY 670 million, indicating a growth of 277.59% to 298.31% compared to the previous year [2] Group 3: Pharmaceutical Business - The pharmaceutical segment includes the development, production, and sales of drug formulations and active pharmaceutical ingredients (APIs), with a focus on skin, anti-infection, and anti-tumor products [4] - The company has established three major API production bases, ensuring a stable supply of core products and achieving integration of API and formulation production [4] Group 4: Research and Development - The company emphasizes R&D in pharmaceuticals, focusing on generic drugs in dermatology and specialty medications, while also investing in innovative drugs through its subsidiary [5] - It holds a 13.2% stake in a company specializing in cell gene therapy, making it the third-largest shareholder [5] Group 5: Medical Services - The company has developed a layered business ecosystem in healthcare, providing integrated medical services that include basic medical care, rehabilitation, and longevity health services [6] - It operates hospitals and health management centers, focusing on disease treatment and health improvement [6][7] Group 6: Health Management - The company has established three longevity and anti-aging centers in major cities, implementing a comprehensive management system for health assessment and intervention [7] - It has partnered with global anti-aging pioneer Bryan Johnson to launch the "Blueprint" anti-aging brand, enhancing its service offerings [8] Group 7: Shareholder Returns - The company has maintained a high dividend policy, distributing approximately CNY 3 billion since 2018, and plans to continue sustainable profit distribution [9] - It is considering diverse dividend methods in the future based on its financial performance [9] Group 8: Bond Issuance - The company plans to issue exchangeable bonds totaling no more than CNY 1 billion, subject to market conditions and shareholder approval [9]

Group 1 - The company Huabang Health announced that its performance forecast for the fiscal year 2025 was disclosed on January 20, 2026 [2]

Group 1 - The company, Huabang Life Health Co., Ltd., has received notification from its controlling shareholder, Chongqing Huabang Zhuoyuan Technology Co., Ltd., regarding the release of part of its pledged shares [1] - As of the announcement date, the cumulative pledge situation of shares held by Huabang Zhuoyuan and its concerted actors, including Mr. Zhang Songshan, Mr. Zhang Yizhuo, and Ms. Zhao Danlin, is detailed [1] - The announcement includes reference to documents such as the "Securities Pledge and Judicial Freezing Details" issued by China Securities Depository and Clearing Corporation Limited [1]

Group 1 - The core point of the announcement is that Huabang Life Health Co., Ltd. has received notification from its controlling shareholder, Chongqing Huibang Zhuoyuan Technology Co., Ltd., regarding the release of a portion of its pledged shares [1] - The announcement includes details about the basic situation of the share pledge release [1] - As of the date of the announcement, the total pledged shares held by Huibang Zhuoyuan and its concerted actors, including Mr. Zhang Songshan, Mr. Zhang Yizhuo, and Ms. Zhao Danlin, are outlined [1] Group 2 - The announcement references specific documents related to the share pledge, including the stock pledge repurchase agreement and statements from the China Securities Depository and Clearing Corporation [2] - The board of directors of Huabang Life Health Co., Ltd. confirms the accuracy and completeness of the information disclosed [1][3] - The announcement is officially issued by the board of directors on January 23, 2026 [4]